Search

The role of the level of prostate specific antigen ( PSA) before initial therapy discusses widely as a prognostic factor in the treatment of prostate cancer (PC ). Despite the fact that many of the questions on the diagnostic and prognostic value of PSA unclear, and new markers of prostate diseases are being introduced with increasing frequency , we assume that the PSA will continue to be one of the main methods of screening and monitoring of patients with prostate cancer, because of its high diagnostic value due to tissue specificity. Using the initial PSA level and Gleason score improves the predictive value significantly. This article presents the results of a retrospective analysis of 307 patients completed the treatment of PC. The effect of baseline PSA level and Gleason score on the choice of treatment , the effectiveness of hormone deprivation and overall survival are evaluated.

Currently, the study of mechanisms of development and introduction of the most effective treatment for castration-resistant prostate cancer (CRPC) – one of the most highlighted problems concerning facing oncologists and urologists worldwide. Several large randomized trials recently (TAX 327 , SWOG 9916) shows high possibilities of combinations based on docetaxel. Results of different treatment schemes on the basis of docetaxel and cabazitaxel in hormone-refractory prostate cancer treatment are presented in this study. The favorable effect is received and justifies further research of efficacy of drug combination.